4,785 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Empire Life Investments Inc.

Empire Life Investments Inc. bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 4,785 shares of the biopharmaceutical company's stock, valued at approximately $5,030,000.

Several other institutional investors also recently added to or reduced their stakes in REGN. Stephens Consulting LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth $26,000. Sachetta LLC increased its holdings in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 10 shares during the period. Crewe Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at about $28,000. Lynx Investment Advisory bought a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $33,000. Finally, Family Firm Inc. acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth about $33,000. 83.31% of the stock is owned by institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, VP Jason Pitofsky sold 487 shares of the business's stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the transaction, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.48% of the company's stock.

Regeneron Pharmaceuticals Trading Up 0.6 %

NASDAQ:REGN traded up $5.40 during trading hours on Friday, hitting $843.60. 1,087,285 shares of the stock were exchanged, compared to its average volume of 768,492. The company has a market capitalization of $93.00 billion, a P/E ratio of 20.88, a price-to-earnings-growth ratio of 2.88 and a beta of 0.15. The company has a quick ratio of 4.62, a current ratio of 5.99 and a debt-to-equity ratio of 0.09. The company's 50 day moving average is $1,058.43 and its two-hundred day moving average is $1,040.85. Regeneron Pharmaceuticals, Inc. has a twelve month low of $783.57 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The firm's revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $8.79 earnings per share. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

REGN has been the subject of several recent research reports. Leerink Partnrs cut Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 24th. Barclays reduced their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating for the company in a research report on Friday. StockNews.com raised shares of Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Tuesday, October 22nd. TD Cowen increased their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a "buy" rating in a research note on Tuesday, July 23rd. Finally, Truist Financial decreased their target price on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a "buy" rating on the stock in a research report on Friday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $1,090.24.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.